Lab Processor offers range of production capabilities.December 12, 2007 -
Powered by 20 A electrical current, M-110P Microfluidizer® laboratory scale processor requires no compressed air or cooling water. Operating pressures from 2,000-30,000 psi enable production of nano-suspensions and nano-emulsions as well as liposomal encapsulation and cell disruption. Portable, bench-top unit supports flow rates from 110-155 ml/min at any process pressure, allowing production of various products. All results are scaleable to pilot and/or production volumes.
(Archive News Story - Products mentioned in this Archive News Story may or may not be available from the manufacturer.)
Original Press release
Microfluidics, Division MFIC Corp.
30 Ossipee Rd.
Newton, MA, 02464 9101
USA
MFIC Corporation Introduces New Product, M-110P Microfluidizer® Processor
NEWTON, MA September 6th, 2007
MFIC Corporation (OTCBB: MFIC), an industry-leader in high-shear processing equipment to produce the most uniform and smallest liquid and solid particles available for the biotech, pharmaceutical, chemical, personal care and food industries announced today the introduction by its operating subsidiary, Microfluidics Corporation, of the M-110P Microfluidizer laboratory scale processor. The M-110P, the Company's first portable bench top plug and play unit, can easily be incorporated into any laboratory setting because it is powered by only standard 20 amp household electrical current and requires no compressed air or cooling water. These features of the M-110P provide a critical formulation solution to customers who have been unable to test and formulate products in the past because they lacked the onsite systems requirements needed to allow them to operate small air operated laboratory units or the three phase electrical requirements needed to operate larger volume laboratory equipment.
The M-110P was designed to operate reliably, quietly and efficiently through a range of operating pressures from 2,000 psi to 30,000 psi, easily enabling the production of nano-suspensions and nano-emulsions, as well as liposomal encapsulation and cell disruption. Importantly, the M-110P also allows for higher flow rates - between 110-155 ml/minute at any process pressure - than any comparable, competitive product, allowing for the production of more sophisticated products including pharmaceutical formulations, fine chemicals, and biological material ranging from simple oil-in-water emulsions to highly immiscible solids-in-liquid suspensions. All results from the M-110P are guaranteed to be scaleable to pilot and/or production volumes, allowing even the smallest customers the ability to fully develop, test, manufacture and produce their products.
"We think the M-110P will play an important role in our long-term growth strategy," said Robert Bruno, President and Chief Operating Officer of MFIC Corporation. "The introduction of the M-110P continues to position MFIC as the industry leader in providing formulation solutions and allows us to reach out to a larger customer base than we have been able to serve previously."
About MFIC Corporation
MFIC Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer® materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics/personal care, and food industries. MFIC applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to MFIC equipment customers.
Contacts:
MFIC Corporation
Jack M. Swig, 617-969-5452
E-mail:
or
MacDougall Biomedical Communications
Sarah Cavanaugh, 508-647-0209
E-mail:
|
|
|
|
|
|
|
| 
